Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism.

Autor:	Hager DN; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Zhu Y; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Sohn I; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Stubblefield WB; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Streiff MB; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Gaglani M; Baylor Scott and White Health, Baylor College of Medicine - Temple, Texas A&M University College of, Medicine, Temple, Texas, USA., Steingrub JS; Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA., Duggal A; Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Felzer JR; Department of Medicine, Emory University, Atlanta, Georgia, USA., O'Rourke M; Department of Emergency Medicine and Medicine, Hennepin County Medical Center, Minneapolis, , Minnesota, USA., Peltan ID; Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah, USA., Mohamed A; Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA., Stiller R; Division of Pulmonary, Allergy and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon, USA., Wilson JG; Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA., Qadir N; Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Ginde AA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Zepeski AE; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA., Mallow C; Department of Medicine, University of Miami, Miami, Florida, USA., Lauring AS; Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA., Johnson NJ; Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA., Gibbs KW; Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA., Kwon JH; Department of Medicine, Washington University, St. Louis, Missouri, USA., Self WH; Department of Emergency Medicine and Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Oct 15. Date of Electronic Publication: 2024 Oct 15.
DOI:	10.1093/infdis/jiae502
Abstrakt:	Background: COVID-19 is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE. Methods: Adults hospitalized at 21 sites between March 2021 and October 2022 with symptoms of acute respiratory illness were assessed for COVID-19, completion of the original monovalent mRNA COVID-19 vaccination series, and VTE. Prevalence of VTE was compared between unvaccinated and vaccinated patients with COVID-19. Vaccine effectiveness in preventing COVID-19 hospitalization with VTE was calculated using a test negative design. Vaccine effectiveness was also stratified by predominant circulating SARS-CoV-2 variant. Results: Among 18,811 patients (median age 63 [IQR:50-73], 49% women, 59% non-Hispanic White, 20% non-Hispanic Black, 14% Hispanic, and median of 2 comorbid conditions [IQR:1-3]), 9,792 were admitted with COVID-19 (44% vaccinated) and 9,019 were test-negative controls (73% vaccinated). Among patients with COVID-19, 601 were diagnosed with VTE by hospital day 28, of whom 170 were vaccinated. VTE was more common among unvaccinated than vaccinated COVID-19 patients (7.8% versus 4.0%; p=0.001). Vaccine effectiveness against COVID-19 hospitalization with VTE was 84% (95% CI: 80-87%) overall. Vaccine effectiveness stratified by predominant circulating variant was 88% (73-95%) for alpha, 93% (90-95%) for delta, and 68% (58-76%) for omicron variants. Conclusions and Relevance: Vaccination with the original monovalent mRNA series was associated with a decrease in COVID-19 hospitalization with VTE, though data detailing prior history of VTE and use of anticoagulation were not available. These findings will inform risk-benefit considerations for those considering vaccination. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu